EA200401504A1 - Слитый белок из числа регуляторных/вспомогательных белков вич - Google Patents

Слитый белок из числа регуляторных/вспомогательных белков вич

Info

Publication number
EA200401504A1
EA200401504A1 EA200401504A EA200401504A EA200401504A1 EA 200401504 A1 EA200401504 A1 EA 200401504A1 EA 200401504 A EA200401504 A EA 200401504A EA 200401504 A EA200401504 A EA 200401504A EA 200401504 A1 EA200401504 A1 EA 200401504A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteins
hiv
nucleic acids
regulatory
auxiliary proteins
Prior art date
Application number
EA200401504A
Other languages
English (en)
Other versions
EA007154B1 (ru
Inventor
Пол Хаули
Соня Лейрер
Ева Фельдер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA200401504A1 publication Critical patent/EA200401504A1/ru
Publication of EA007154B1 publication Critical patent/EA007154B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к слитым белкам, включающим аминокислотную последовательность по меньшей мере четырех ВИЧ-белков, выбранных из Vif, Vpr, Vpu, Rev, Tat и Nef, или производные аминокислотной последовательности одного или нескольких указанных белков, где данный слитый белок не процессируется до индивидуальных ВИЧ-белков, обладающих естественными N- и C-концами. Кроме того, настоящее изобретение относится к нуклеиновым кислотам, кодирующим указанные белки, векторам, включающим указанные нуклеиновые кислоты, и к способам получения указанных белков. Данные слитый белок, нуклеиновые кислоты и векторы применимы в качестве вакцин, по меньшей мере, для частичной профилактики против ВИЧ-инфекций.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401504A 2002-05-16 2003-05-14 Слитый белок из числа регуляторных/вспомогательных белков вич EA007154B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200754 2002-05-16
PCT/EP2003/005039 WO2003097675A1 (en) 2002-05-16 2003-05-14 Fusion protein of hiv regulatory/accessory proteins

Publications (2)

Publication Number Publication Date
EA200401504A1 true EA200401504A1 (ru) 2005-04-28
EA007154B1 EA007154B1 (ru) 2006-08-25

Family

ID=29433046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401504A EA007154B1 (ru) 2002-05-16 2003-05-14 Слитый белок из числа регуляторных/вспомогательных белков вич

Country Status (24)

Country Link
US (7) US20050222388A1 (ru)
EP (2) EP1652857B9 (ru)
JP (3) JP2006502704A (ru)
KR (4) KR101196178B1 (ru)
CN (3) CN1982332A (ru)
AT (2) ATE407143T1 (ru)
AU (2) AU2003240638B2 (ru)
BR (1) BR0309963A (ru)
CA (1) CA2483640A1 (ru)
CY (1) CY1108638T1 (ru)
DE (2) DE60323407D1 (ru)
DK (2) DK1652857T3 (ru)
EA (1) EA007154B1 (ru)
ES (2) ES2313166T3 (ru)
HK (1) HK1076822A1 (ru)
IL (3) IL164178A0 (ru)
MX (1) MXPA04010683A (ru)
NO (1) NO20045229L (ru)
NZ (2) NZ536499A (ru)
PL (2) PL397252A1 (ru)
PT (1) PT1652857E (ru)
SI (2) SI1652857T1 (ru)
UA (3) UA82998C2 (ru)
WO (1) WO2003097675A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101196178B1 (ko) * 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
ATE520708T1 (de) 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
IN2014DN06624A (ru) 2005-10-18 2015-07-10 Univ Colorado
CA2659275C (en) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
AU2007345682B2 (en) * 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2313496T3 (en) 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
SG178909A1 (en) * 2009-10-08 2012-04-27 Bavarian Nordic As Generation of a broad t-cell response in humans against hiv
EP2485759A4 (en) * 2009-10-09 2013-07-24 Univ New York METHODS, AGENTS AND PEPTIDES FOR INDUCING IMMUNE RESPONSE INNEED IN VACCINATION AGAINST HIV
JP5917402B2 (ja) 2009-11-03 2016-05-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10196426B1 (en) * 2014-06-18 2019-02-05 Sun Yat-Sen University Chimeric vector and preparation method and use thereof
CN104130331B (zh) * 2014-06-19 2017-06-06 中山大学 一种抗hiv‑1病毒药物及其制备和应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN105330729A (zh) * 2015-11-18 2016-02-17 南京医科大学 一种人类免疫缺陷病毒Vpr蛋白的制备方法
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FI105105B (fi) 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CZ20022643A3 (cs) 2000-01-31 2003-02-12 Smithkline Beecham Biologicals S. A. Farmaceutický prostředek
US20020106798A1 (en) * 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7488484B2 (en) * 2000-07-14 2009-02-10 The Trustees Of The University Of Pennsylvania Nucleic acid expression cassette encoding an HIV polyprotein comprising the ancillary gene products Vif, Vpu, and Nef
AU2872202A (en) * 2000-11-01 2002-05-15 Us Gov Health & Human Serv Expression vectors able to elicit improved immune response and methods of using same
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
KR101196178B1 (ko) * 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질

Also Published As

Publication number Publication date
US8435535B2 (en) 2013-05-07
EA007154B1 (ru) 2006-08-25
ES2253675T3 (es) 2006-06-01
KR20100063126A (ko) 2010-06-10
CN1982332A (zh) 2007-06-20
JP2010099084A (ja) 2010-05-06
US20100047871A1 (en) 2010-02-25
UA82998C2 (ru) 2008-06-10
ATE407143T1 (de) 2008-09-15
EP1506223B1 (en) 2005-11-16
AU2008252074B2 (en) 2012-02-16
DE60323407D1 (de) 2008-10-16
US8147839B2 (en) 2012-04-03
US7569228B2 (en) 2009-08-04
UA85373C2 (ru) 2009-01-26
UA92788C2 (ru) 2010-12-10
DK1652857T3 (da) 2009-01-05
US20120142096A1 (en) 2012-06-07
US20090280561A1 (en) 2009-11-12
NZ536499A (en) 2008-04-30
US20060257974A1 (en) 2006-11-16
HK1076822A1 (en) 2006-01-27
IL164178A0 (en) 2005-12-18
JP2006502704A (ja) 2006-01-26
CN1653085A (zh) 2005-08-10
KR20110099058A (ko) 2011-09-05
PL397252A1 (pl) 2012-04-10
EP1506223A1 (en) 2005-02-16
US20120142097A1 (en) 2012-06-07
KR20120106894A (ko) 2012-09-26
PT1652857E (pt) 2008-12-12
EP1652857A2 (en) 2006-05-03
JP2009178165A (ja) 2009-08-13
DK1506223T3 (da) 2006-04-10
US8137931B2 (en) 2012-03-20
KR20050010000A (ko) 2005-01-26
AU2003240638B2 (en) 2008-05-15
CY1108638T1 (el) 2014-04-09
NZ556144A (en) 2008-04-30
SI1506223T1 (sl) 2006-04-30
KR100996330B1 (ko) 2010-11-23
EP1652857B1 (en) 2008-09-03
US8143054B2 (en) 2012-03-27
NO20045229L (no) 2004-11-29
ES2313166T3 (es) 2009-03-01
DE60302356D1 (de) 2005-12-22
EP1652857A3 (en) 2007-03-14
DE60302356T2 (de) 2006-08-03
US8389275B2 (en) 2013-03-05
CN1325512C (zh) 2007-07-11
PL372092A1 (en) 2005-07-11
CN101108882A (zh) 2008-01-23
EP1652857B9 (en) 2009-10-14
IL197304A0 (en) 2011-07-31
AU2003240638A1 (en) 2003-12-02
ATE310016T1 (de) 2005-12-15
CA2483640A1 (en) 2003-11-27
SI1652857T1 (sl) 2009-02-28
US20100047268A1 (en) 2010-02-25
IL164178A (en) 2011-01-31
AU2008252074A1 (en) 2009-01-08
KR101196178B1 (ko) 2012-11-01
MXPA04010683A (es) 2005-02-17
BR0309963A (pt) 2005-02-22
WO2003097675A1 (en) 2003-11-27
US20050222388A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
CY1108638T1 (el) Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
ATE286978T1 (de) Rekombinante hiv-2 antigenen, abgeleitete aus synthetischen dns
ATE317903T1 (de) Pflanzen lysophosphatidesäure-acyltransferase
DK0668931T3 (da) Nucleinsyreligander og fremgangsmåder til fremstilling heraf
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
WO2005047483A3 (en) Renta: an hiv immunogen and uses thereof
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
NO179010C (no) Antistoffer mot höyt konserverte aminosyresekvenser fra immunogene forbindelser og anvendelse derav i immunoanalyser
CY1113749T1 (el) Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU